EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

News
Video

Terence Friedlander, MD, presents significant data from the EV-302/KEYNOTE-A39 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Related Videos
Jonathan E. Rosenberg, MD
Joaquim Bellmunt, MD, PhD
Arlene O. Siefker-Radtke, MD
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Mark D. Tyson, II, MD, MPH
Jonathan E. Rosenberg, MD
Joaquim Bellmunt, MD, PhD
Related Content
Vikram M. Narayan, MD, Emory University Hospital; director, urological oncology, Grady Memorial Hospital; assistant professor, Department of Urology, Emory University School of Medicine; member, Winship Cancer Institute

Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC

May 15th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Joaquim Bellmunt, MD, PhD

EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer

May 10th 2024
Article
Terence Friedlander, MD

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023
Podcast
Antoni Vilaseca Cabo, MD, of Hospital Clínic de Barcelona

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

May 5th 2024
Article
Vikram Narayan, MD

Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC

May 5th 2024
Article